logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Field Evaluation of Near Point of Care Cepheid GeneXpert HIV-1 Qual for Early Infant Diagnosis | Journal Article / Research | MSF Science Portal
Journal Article
|Research

Field Evaluation of Near Point of Care Cepheid GeneXpert HIV-1 Qual for Early Infant Diagnosis

Opollo VS, Nikuze A, Ben Farhat J, Anyango E, Humwa F, Oyaro B, Wanjala S, Omwoyo W, Majiwa M, Akelo V, Zeh C, Maman D
Download

Similar Content
Loading...
Loading...
Loading...
Abstract
Access to point-of-care HIV testing shortens turn-around times, time to diagnosis and reduces loss to follow-up hence minimizing barriers to early linkage to care and treatment among HIV infected infants. Currently samples for early infant HIV diagnosis are sent to centralized testing facilities which are few and located only at specific regions in Kenya. However, there are Point of Care (POC) early infant diagnosis [EID] technologies elsewhere such as SAMBA and ALERE-Q that are yet to be evaluated in Kenya despite the urgent need for data to inform policy formulation regarding EID. The Cepheid GeneXpert HIV-1 Qual (GeneXpert) technology for POC EID offers a great opportunity to minimize HIV associated morbidity, mortality and loss to follow-up through decentralization of early infant HIV testing to the clinics. This technology also allows for same-day results thus facilitating prompt linkage to care.

Countries

Kenya

Subject Area

pediatricsHIV/AIDS

Languages

English
DOI
10.1371/journal.pone.0209778
Published Date
27 Dec 2018
PubMed ID
30589900
Journal
PLOS One
Volume | Issue | Pages
Volume 13, Issue 12
Issue Date
2018-12-27
Dimensions Badge